Table 1.
Baseline clinical characteristics and follow-up measures of participants from all study cohorts.
| GHS | TVAS | CREED | GMS | JKS | |
|---|---|---|---|---|---|
| Number | 354 | 102 | 265 | 714 | 416 |
| Male (%) | 67.8 | 86.3 | 55.8 | 46.1 | 56.7 |
| Age (yrs) | 64.5±8.1 | 61.9±9.3 | 61.0±15.4 | 61.8±9.8 | 43.7±9.0 |
| BMI (kg/m2) | 30.2±4.8 | 28.0±3.9 | 24.9±4.4 | 31.1±5.9 | 29.9±6.5 |
| Diabetes (%) | 100 | 15.7 | 16.2 | 100 | 100 |
| anti-hyperglycaemic Tx (%) | 89.6 | 0* | 100 | 86.8 | 91.5 |
| Hypertension (%) | 84.7 | 99.0 | 72.8 | 50.3 | 55 |
| anti-hypertensive Tx (%) | 84.3 | 95.4 | 41 | 49.2 | 46.5 |
| Follow-up (yrs) | 5.3±2.5 | 5.9±1.9 | 3.4±1.8 | 7.6±2.1 | 12.8±5.8 |
| Follow-up (py) | 1,876 | 602 | 901 | 5,426 | 5,325 |
| Events (n) | 79 | 12 | 141 | 127 | 214 |
Continuous variables were reported as mean±SD whereas categorical variables as percentages.
GHS: Gargano Heart Study-prospective design; TVAS: Tor Vergata Atherosclerosis Study; CREED: Cardiovascular Risk Extended Evaluation in Dialysis database; GMS: Gargano Mortality Study; JKS: Joslin Kidney Study in type 2 diabetes; BMI: body mass index; py: person-years. Tx: treatment.
*
TVAS diabetic patients were all neodiagnosed at study entry.